A look at using best practice tech transfer methods for CGTs to increase process and analytics robustness while being scalable.
Matthew Hewitt
Advertisement
Matthew Hewitt is vice-president, technical officer, Cell & Gene Therapy & Biologics at Charles River Laboratories.
Articles by Matthew Hewitt
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
3
Janux’s JANX011 T-Cell Engager Shows Deep B-Cell Depletion in Phase 1 Healthy Volunteer Study
4
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
5